Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 105, Issue 11, Pages 1628-1634
Publisher
Springer Nature
Online
2011-10-19
DOI
10.1038/bjc.2011.385
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2011) Nicolas Mottet et al. EUROPEAN UROLOGY
- Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial
- (2011) James W Denham et al. LANCET ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of Androgen Deprivation Therapy Efficacy Combined With Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose
- (2010) Scott Williams et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- 7007 Three years of adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: Results at 10 years of EORTC trial 22863
- (2009) M. Bolla et al. EJC SUPPLEMENTS
- Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
- (2009) Bertrand Tombal et al. EUROPEAN UROLOGY
- Is Biochemical Response More Important Than Duration of Neoadjuvant Hormone Therapy Before Radiotherapy for Clinically Localized Prostate Cancer? An Analysis of the 3- Versus 8-Month Randomized Trial
- (2009) Abraham Alexander et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Duration of Androgen Suppression in the Treatment of Prostate Cancer
- (2009) Michel Bolla et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
- Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer
- (2008) Hendrik Van Poppel et al. EUROPEAN UROLOGY
- Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610
- (2008) Mack Roach et al. JOURNAL OF CLINICAL ONCOLOGY
- Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
- (2008) Eric M. Horwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America
- (2008) Marc Gittelman et al. JOURNAL OF UROLOGY
- Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
- (2008) Anders Widmark et al. LANCET
- Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?
- (2008) Hendrik van Poppel et al. UROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started